Detalhe da pesquisa
1.
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
Am J Respir Crit Care Med
; 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38564365
2.
Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First Trimester.
Clin Infect Dis
; 78(3): 667-673, 2024 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768207
3.
Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.
Clin Infect Dis
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568956
4.
Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Clin Infect Dis
; 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462673
5.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
N Engl J Med
; 384(18): 1705-1718, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951360
6.
Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.
J Viral Hepat
; 31(5): 221-232, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38545826
7.
Convergent and divergent oscillatory aberrations during visuospatial processing in HIV-related cognitive impairment and Alzheimer's disease.
Cereb Cortex
; 33(6): 3181-3192, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855581
8.
Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA.
Mol Cell
; 62(2): 157-168, 2016 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27105112
9.
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
Am J Respir Crit Care Med
; 207(10): 1376-1382, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36790881
10.
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Clin Infect Dis
; 76(3): e580-e589, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041016
11.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36660819
12.
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis.
Clin Infect Dis
; 77(6): 892-900, 2023 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227925
13.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130809
14.
Mitochondrial redox environments predict sensorimotor brain-behavior dynamics in adults with HIV.
Brain Behav Immun
; 107: 265-275, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36272499
15.
Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment.
Clin Infect Dis
; 75(Suppl 4): S510-S516, 2022 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36410384
16.
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments.
Clin Infect Dis
; 75(1): 3-10, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699587
17.
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Clin Infect Dis
; 75(4): 560-566, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34918028
18.
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Antimicrob Agents Chemother
; 66(9): e0238521, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35943252
19.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33308425
20.
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
N Engl J Med
; 380(11): 1001-1011, 2019 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865794